Categories
Mucositis severe

[PDF] Severe Oral Mucositis Market on inorganic strategies and fund raising activities

Oral mucositis refers to tissue swelling in the mouth. Radiation therapy or chemotherapy may cause mucositis. Oral mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer who are treated with chemotherapy, and/or with radiation therapy. Lesions of oral mucositis are often very painful and compromise nutrition and oral hygiene as…

Oral mucositis refers to tissue swelling in the mouth. Radiation therapy or chemotherapy may cause mucositis. Oral mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer who are treated with chemotherapy, and/or with radiation therapy. Lesions of oral mucositis are often very painful and compromise nutrition and oral hygiene as well as increase the risk for local and systemic infection. Oral mucositis is a significant and dose-limiting toxicity of cancer therapy with important clinical and economic implications. Oral mucositis from chemotherapy or radiation treatment can last from 7 to 98 days.

The key players in the market are focused on growth strategies such as FDA approvals, which are expected to drive the growth of the market over forecast period. For instance, in November 2016, Oragenics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AG013, the company’s lead therapeutic candidate for the treatment of oral mucositis. Furthermore, in April 2018, Enzychem Lifesciences announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EC-18 for the treatment of chemo-radiation induced oral mucositis. Moreover, key companies focusing on research and development of severe oral mucositis are expected to drive the growth of the market over forecast period. For instance, in December 2019, Oragenics, Inc., announced the completion of enrolment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, which is an easy-to-use oral rinsing system designed to prevent and treat oral mucositis.

Request for a PDF sample of this report:
https://www.coherentmarketinsights.com/insight/request-sample/4571

The key players in the U.S. are focusing on fund raising activities for boosting research and development for the treatment of severe oral mucositis caused due to radiation and chemotherapy in the cancer patients. For instance, in September 2018, Galera Therapeutics, Inc., a company developing novel mechanism-based therapies, announced that the company secured US$ 150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, and Tekla Capital Management LLC. The existing investors Corre

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *